The association of well-being, productivity and resource use among community-dwelling patients with schizophrenia using atypical antipsychotics

被引:2
作者
DiBonaventura, Marco Dacosta [1 ]
Panish, Jessica
Kenworthy, Debbie [2 ]
Wagner, Jan-Samuel [2 ]
Dirani, Riad
机构
[1] Kantar Hlth, New York, NY USA
[2] Ortho McNeil Janssen Sci Affairs LLC, Titusville, NJ USA
关键词
atypical antipsychotics; healthcare resource use; schizophrenia; well-being; productivity;
D O I
10.1111/j.1759-8893.2010.00033.x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective The aim of the current study was to examine levels of well-being and productivity and the interrelationships between them in community-dwelling patients with schizophrenia who use atypical antipsychotic medications. Methods A mixed methodology (online and paper surveys) was implemented to recruit patients in the USA over the age of 18 years who were diagnosed with schizophrenia by a healthcare professional and who were able to read and write English. Patients who were currently being treated with an atypical medication and provided well-being data (n = 745) were included in the analyses. Logistic and negative binomial regressions were used to determine the effect of well-being on productivity and resource use. Key findings Almost two-thirds of patients taking atypical antipsychotics reported low levels of well-being (63%). After controlling for demographic and patient characteristics, patients with low levels of well-being were significantly less likely to be employed and productive than patients with moderate or high levels of well-being (P < 0.05). Similarly, patients with low levels of well-being were significantly more likely to be hospitalized or visit the emergency room relative to patients with high levels of well-being (P < 0.05). Conclusions The results suggest that there may be an unmet need among patients with schizophrenia who use atypical antipsychotic medications. Overall levels of well-being were low in these community-dwelling patients. Further, low levels of well-being were found to be significantly related to worse productivity and, to a certain extent, additional resource use, after controlling for a variety of confounding variables. Although additional research is necessary, improved disease management and use of innovative antipsychotic medications, such as long-acting injectables, may benefit these patients by improving well-being, productivity and resource use.
引用
收藏
页码:181 / 187
页数:7
相关论文
共 22 条
[1]   Is quality of life associated with cognitive impairment in schizophrenia? [J].
Alptekin, K ;
Akvardar, Y ;
Akdede, BBK ;
Dumlu, K ;
Isik, D ;
Pirinçci, F ;
Yahssin, S ;
Kitis, A .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2005, 29 (02) :239-244
[2]  
American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th., DOI DOI 10.1176/APPI.BOOKS.9780890425787
[3]  
Bagnall A-M, 2003, Health Technol Assess, V7, P1
[4]   Quality of life in schizophrenia: A comparison of instruments [J].
Cramer, JA ;
Rosenheck, R ;
Xu, WC ;
Thomas, J ;
Henderson, W ;
Charney, DS .
SCHIZOPHRENIA BULLETIN, 2000, 26 (03) :659-666
[5]   A meta-analysis of the efficacy of second-generation antipsychotics [J].
Davis, JM ;
Chen, N ;
Glick, ID .
ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (06) :553-564
[6]  
Dixon L, 2009, APA PRACTICE GUIDELI
[7]  
Dupuy HJ., 1984, ASSESSMENT QUALITY L, P170
[8]   Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis [J].
Geddes, J ;
Freemantle, N ;
Harrison, P ;
Bebbington, P .
BRITISH MEDICAL JOURNAL, 2000, 321 (7273) :1371-1376
[9]   Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia - Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) [J].
Jones, Peter B. ;
Barnes, Thomas R. E. ;
Davies, Linda ;
Dunn, Graham ;
Lloyd, Helen ;
Hayhurst, Karen P. ;
Murray, Robin M. ;
Markwick, Alison ;
Lewis, Shon W. .
ARCHIVES OF GENERAL PSYCHIATRY, 2006, 63 (10) :1079-U6
[10]   The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis [J].
Keefe, RSE ;
Silva, SG ;
Perkins, DO ;
Lieberman, JA .
SCHIZOPHRENIA BULLETIN, 1999, 25 (02) :201-222